Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Intensity Therapeutics Inc. | INT230-6 in combination with Yervoy | Triple Negative Breast Cancer, Sarcomas, Hepatic Cancers | Phase 2 | Trial Completed | Intratumoral and intravenous | Oncology |
| Intensity Therapeutics Inc. | INT230-6 - (INVINCIBLE-4) | Triple Negative Breast Cancer | Phase 2 | Data Released | intratumoral | Oncology |
| Inventiva S.A. | Lanifibranor | Nonalcoholic fatty liver disease (NAFLD) | Phase 2 | Ongoing | Oral | Gastroenterology |
| Inventiva S.A. | Cedirogant (ABBV-157) | Psoriasis | Phase 2b | Trial Discontinued | Oral | Immunology |
| Inventiva S.A. | Lanifibranor - (NATIVE) | Non-alcoholic steatohepatitis (NASH) | Phase 2b | Data Released | Oral | Gastroenterology |
| Inventiva S.A. | Lanifibranor in combination with empagliflozin (Jardiance1) - (LEGEND) | Metabolic dysfunction-associated steatohepatitis (MASH), and type 2 diabetes (T2D) | Phase 2a | Trial Completed | Oral | Endocrinology |
| Inventiva S.A. | Lanifibranor - (NATiV3) | Nonalcoholic steatohepatitis (NASH) | Phase 3 | Data Released | Oral | Gastroenterology |
| Invitae Corporation | Elsunersen (PRAX-222) - (EMBRAVE) | Early-seizure-onset SCN2A developmental and epileptic encephalopathy (DEE) | Phase 2 | Data Released | Intrathecal | Neurology |
